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Abstract 
Background 
Since a national lockdown was introduced across the UK in response to the COVID-19 pandemic, 
cancer screening has been suspended, routine diagnostic work deferred, and only urgent symptomatic 
cases prioritised for diagnostic intervention. In this study we estimate the impact of delays in diagnosis 
on cancer survival outcomes in four major tumour types.  
Methods 
The study uses linked English National Health Services (NHS) cancer registration and hospital 
administrative datasets for patients aged 15-84, diagnosed between 01/01/2010 and 31/12/2010 with 
follow-up until 31/12/2014 for breast (n=32,583), colorectal (n=24,975), and oesophageal cancer (n= 
6,744), and for lung cancer patients (n= 29,305) diagnosed between 01/01/2012 and 31/12/2012 with 
follow-up until 31/12/2015. We use a ‘routes to diagnosis’ framework to estimate the impact of 
diagnostic delay over a 12-month period from the commencement of lockdown measures, 
16/03/2020. We reallocate patients who were on screening and routine referral pathways to urgent 
and emergency pathways, which are associated with more advanced stage of disease at diagnosis. We 
consider three reallocation scenarios which reflect actual changes in the diagnostic pathway being 
seen in the NHS, and estimate the impact on net survival at 1, 3 and 5 years to calculate the additional 
deaths that can be attributed to cancer, and the total years of life lost (YLL) compared to pre-pandemic 
figures.  
Findings 
Across the three scenarios, compared to pre-pandemic figures, we estimate an 8-10% increase in the 
number of deaths due to breast cancer up to Year 5, corresponding to between 281 (266-295) and 
344 (329-358) additional deaths. For colorectal cancer we estimate 1,445 (1,392-1,591) to 1,563 
(1,534-1,592) additional deaths (a 15-17% increase); lung cancer 1,235 (1,220-1,254) to 1,372 (1,343-
1,401) additional deaths (5% increase) and oesophageal cancer 330 (324-335) to 342 (336-348) 
additional deaths (6% increase). For these four tumour types, this corresponds to a total of 3,291 to 
3,620 additional deaths across the scenarios within 5 years. The total additional years of life lost (YLL) 
across these cancers is estimated to be between 59,203 to 63,229 years.  
Interpretation  
There are expected to be substantial increases in the number of avoidable cancer deaths in the UK, 
predominantly related to the expected increase in diagnoses following an emergency presentation. 
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Urgent policy interventions are necessary, in particular the need to manage the backlog within routine 
diagnostic services, to mitigate the expected impact of the COVID-19 pandemic on cancer patients.  
Funding 
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Innovation Global Challenge Research Fund (RS) 
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Background 
A national lockdown was introduced across the United Kingdom (UK) on 23rd March 2020, as part of 
the national strategy to ‘flatten the curve’ of the COVID-19 pandemic and reduce the potential impact 
on the National Health Service (NHS).1 This has been associated with a decline in, or cessation of, most 
non-COVID-19 NHS services, increasing concern about the impact this will have on other patient 
groups requiring time-critical access to health care services. This includes cancer patients for whom 
timely diagnosis and the prompt initiation of treatment is vital for ensuring optimal outcomes.2,3  
During the pandemic, multiple changes in the provision of cancer care from the point of diagnosis, 
including modification of treatment schedules (change in therapy, deferral or omission), have been 
advised by professional bodies and commissioners of services.4-7 However, there is significant 
heterogeneity in the implementation of these recommendations across providers nationally and for 
individual patients. Such variations in the extent of treatment delay, and in changes to treatment 
doses and schedules (including new treatment techniques) means that at a population level it is 
challenging to model these variations in practice on cancer outcomes. 
Instead, we focus on analysing the impact of changes in cancer diagnostic pathways and subsequent 
delays in diagnosis during the COVID-19 pandemic. It is already evident that routine non-urgent 
diagnostic work initiated by referral from both general practitioners (GPs) and secondary care teams 
(for radiology or endoscopic procedures,8 for example) has been deferred across the UK. Cancer 
screening services have been suspended, and patients’ only routes to diagnosis in recent weeks has 
been via urgent ‘two-week wait’ (2WW) suspected cancer pathway referrals initiated by the GP or 
through direct presentation to an emergency department.9  Patients are eligible for these rapid access 
two-week wait (2WW) pathways to access diagnostic investigations, on the basis of their age, 
symptom profile (e.g. dysphagia), signs (e.g. breast lump) or results of investigations (e.g. iron 
deficiency anaemia) as specified by guidelines developed by the National Institute for Health and Care 
Excellence (NICE).9   
However, since March 2020, there has been evidence of changes in health seeking behaviour with 
urgent 2WW cancer referrals falling by up to 80% in response to social distancing, and concerns about 
contracting SARS-Cov2 virus.10 In addition, some form of social distancing is expected to continue for 
up to 12 months, which will impact further on health care presentations.11,12  
Quantifying the exact impact of delays in diagnosis on stage and prognosis are complex, but a ‘routes 
to diagnosis’ approach provides a validated methodological framework for understanding their 
impacts. Work by Ellis-Brookes et al.13 demonstrated that referral routes to diagnosis are 
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characterised by differences in both stage at presentation and survival. For example, urgent 2WW 
suspected cancer referrals and emergency presentations are associated with later-stage of disease at 
diagnosis compared to patients diagnosed through routine GP and secondary care referral routes and 
screening. In addition, diagnosis following initial presentation to an emergency department is 
consistently associated with the worst survival outcomes compared to all other routes.13  
Given the changes in health seeking behaviour and the availability and access to diagnostic services as 
a result of the COVID-19 lockdown, these ’routes to diagnosis’ provide a framework for estimating the 
impact of these changes on stage migration and excess mortality, based on patients moving to 
different referral routes during the pandemic.  
The effect of delayed presentation on cancer patients is not immediate, and premature death as a 
result may occur up to 5 years later and will differ according to tumour type. In this study we consider 
the impact on four major tumour types: breast, colorectal, lung, and oesophagus because they differ 
in their predominant routes to referral (including screening), stage at presentation, and both short- 
and long-term prognoses according to stage. Using national population datasets of patients diagnosed 
and treated in the English National Health Service (NHS) we estimate the impact of delays in diagnosis 
that are attributed to the measures put in place to halt the COVID-19 pandemic in the UK. We estimate 
their effect on patient survival and the number of additional deaths expected due to these cancers, as 
well as the additional years of life lost. 
Methods 
Conceptual framework 
Based on previous years’ trends we assume that the incidence of each of the four tumour types will 
remain relatively stable year on year,14 and that the current pandemic and subsequent lockdown will 
mean patients will be more likely to delay presentation. We estimate the subsequent impact on 
survival, by reallocating patients from screening and non-urgent routine referral pathways (from GPs 
and secondary care) to urgent pathways, namely 2WW referral routes and emergency presentation. 
Both of these urgent pathways are associated with later stage of diagnosis and enable us to estimate 
the impact of diagnostic delay on stage migration and survival outcome.  
We justify our reallocation model on four assumed factors: 1. 2WW and emergency pathways are the 
only referral routes at the present time; 2. While routine diagnostic work and non-urgent referral 
pathways are delayed and screening suspended, some patients awaiting investigation will become 
symptomatic as their cancer progresses and will meet the criteria for urgent 2WW suspected cancer 
referrals or present as emergencies direct to secondary care; 3. For patients awaiting routine 
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diagnostic investigations from GP and secondary care referrals there are expected to be significant 
delays (>6 months) in this pathway,12 due to the backlogs of routine work across all medical and 
surgical services increasing the likelihood of disease progression, which we estimate through 
reallocation to 2WW and emergency pathways. 4. Changes in health seeking behaviour as a result of 
the pandemic means that some patients will delay presentation until more prominent symptoms 
develop, and these patients will be more likely to present through 2WW and emergency pathways.  
The starting point for our estimation is from the 16th March 2020, which is the date social distancing 
measures were introduced, and the impact is modelled over a 12-month period to account for the 
expected duration of disruption to services and patterns of referral. This-period defines our cohort of 
expected number of cancer diagnoses for each tumour type, but It is acknowledged that patients may 
present and be diagnosed beyond this period due to diagnostic delay. Our model reallocates patients 
based on pre-pandemic ratios. For example, if 10% of new diagnoses for a given tumour type is 
following an emergency department presentation, and 90% via an outpatient referral, our simulation 
analysis will maintain these proportions when reallocating patients from screening and routine 
referral pathways.   
For breast cancer patients diagnosed through the screening referral pathway, we accounted for the 
fact that many are diagnosed with pre-invasive disease15 or disease that is unlikely to progress even 
within a 12-month period. We therefore reallocated only 25% (n=2,700) of breast cancer screening 
patients. This reflects the proportion of screening patients with T3, T4, node positive or metastatic 
disease at the time of diagnosis. Reallocation was used to estimate the excess mortality compared to 
the pre-pandemic period.  
 Scenarios 
We based our analysis on three sets of predictions according to possible changes in referral patterns 
(Figure 1) representing best/worst case scenarios: 
Scenario A – We estimate survival outcomes for patients by reallocating those who are expected to 
be diagnosed through screening and routine referral pathways (GP or secondary care) to 2WW and 
emergency presentation pathways, from 16th March 2020.   
Scenario B - As per scenario A, but from 16th March we simulate the impact of an 80% reduction in 
2WW referrals already observed during the lockdown period, and assume that this reduction will 
continue (due to COVID-19-related concerns) for up to three months. Emergency presentations are 
assumed to continue at their usual rate. We therefore re-allocate the backlog of patients in Months 
4-12 to 2WW pathways and emergency presentations. 
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Scenario C – As per Scenario B, but we simulate the impact of 2WW referrals continuing to be reduced 
beyond the first three-month period by 25% for a further three-month period, that is until Month 6 
post introduction of social distancing measures. Emergency presentations are assumed to continue at 
the usual rate. We therefore re-allocate the backlog of patients in Months 7-12 to 2WW pathways and 
emergency presentations. 
Population and datasets 
Information on adults with non-small cell lung cancer (NSCLC, hereafter “lung cancer” ICD-10: C33, 
C34), cancers of the colon (ICD-10: C18) and rectum (ICD-10: C19), cancers of the oesophagus and 
gastro-oesophageal junction (ICD-10: C15, C16.0) and women with breast cancer (ICD-10: C50) were 
obtained from the National Cancer Registration Service (NCRS). The pre-pandemic cohort refers to 
patients diagnosed between 01/01/2010 and 31/12/2010 with follow-up until 31/12/2014 for 
cancers of the colon, rectum, oesophagus and breast, and to patients diagnosed between 
01/01/2012 and 31/12/2012 with follow-up until 31/12/2015 for lung cancer. We restricted the 
analyses to patients aged 15-84 years at diagnosis and those who had a known route of diagnosis 
coded (91% for colorectal cancer, 93% for oesophagus, 94% for breast and 97 % for lung).  
 
The NCRS records and updates patient and tumour characteristics for virtually all cancers (98-100%) 
diagnosed in England.16 Information on referral pathway is derived from linkages of the cancer 
registrations with secondary care data (Hospital Episode Statistics, HES), screening records, and cancer 
waiting times data.13 These linkages were performed with deterministic linkage using the NHS 
Number, with a linkage success of 99-100%.16 Information on patient’s comorbidity status is derived 
from HES diagnostic codes when patients attend hospital.17 Levels of deprivation are determined by 
the quintiles of the Index of Multiple Deprivation (IMD) income domain, for the patients’ residential 
postcodes, measured at Lower Super Output Area level.18 This study has been undertaken in 
accordance with existing statutory and ethical approvals from the Confidentiality Advisory Group and 
Research Ethics Committee (PIAG 1-05(c)/2007 and REC 13/LO/0610). 
Statistical analyses 
The mode of presentation and dates of diagnosis of the pre-pandemic cohorts were randomly 
modified according to scenarios A-C. Patients diagnosed through screening and routine referral 
pathways (outpatient or inpatient), were reallocated to either emergency presentation or 2WW 
referral routes. For scenarios B and C, we reallocated a proportion of patients diagnosed through the 
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2WW pathway as these referral routes are expected to operate at 20% and 75% of their capacity as 
previously described.  
The reallocation of patients from routine and screening pathways to the emergency presentation 
route was estimated at the same proportion observed in the pre-pandemic cohorts: 930 (2.9%) of 
32,583 patients for breast, 4,143 (26.1%) of 15,867 patients for colon, 1,040 (11.4%) of 9,108 
patients for rectum, 9,636 (32.9%) of 29,305 patients for lung, and 1,228 (18.2%) of 6,744 patients 
for oesophageal cancer (Table 1).  
 
Whilst pre-pandemic patients diagnosed through emergency routes were more likely to be older and 
have more comorbidities; during this pandemic significant changes have been noted to the availability 
of diagnostic services through both routine and 2WW referral pathways, which has affected all 
patients. In addition, there has been evidence of changes in health seeking behaviour resulting in an 
80% reduction in the volume of urgent 2WW referrals since the UK lockdown. We therefore account 
for the fact that new groups of patients with a different sociodemographic profile are likely to first 
present with cancer following an emergency admission and therefore reallocate any patient in the 
cohort to either the urgent 2WW referral or emergency presentation route. 
To estimate the impact that the response to COVID-19 could have on cancer survival, we compared 
the net survival of pre-pandemic cohorts of cancer patients to that of patients diagnosed according to 
the postulated scenarios A to C. Of note for colorectal cancer even though the reallocation from 
routine to urgent pathways was undertaken separately for patients with rectal and colon cancer, the 
survival estimates are for the combined colorectal cancer population. We translated the differences 
in net survival between pre-pandemic and pandemic cohorts into the number of deaths due to cancer 
for each scenario. Compared to the number of deaths due to cancer in the pre-pandemic cohorts, we 
derived the additional number of deaths due to cancer and additional number of years of life 
expectancy lost. Confidence intervals were calculated using bootstrap resampling. 
These estimates are obtained from multivariable excess hazard models. When analysing population-
based data, the measure of interest, excess mortality due to cancer, is conventionally retrieved by 
removing the impact of competing risks of death, i.e. deaths from causes other than the cancer of 
interest.19 These competing risks are derived from general population life tables, defined by sex, single 
years of age, calendar years, deprivation quintile, and Government Office Regions. All-cause mortality 
from general population life tables does include cancer-related mortality but each site-specific 
mortality represents a negligible cause of death and therefore does not impact the estimation of 
cancer survival.20,21 Further details and mathematical formulas are provided in the Web-Appendix, 
pages 1-3. All statistical analyses were performed using Stata version 16. 
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Role of the funding source 
None of the co-author funding sources had any role in the study design, data collection, data analysis, 
data interpretation, writing of the report, or decision to submit for publication. CM, BR and AA had 
full access to all the data in the study, take responsibility for the integrity of the data and accuracy of 
the data analysis, and had final responsibility for the decision to submit to publication.  
Results 
We analysed data on 32,583 breast, 24,975 colorectal, 29,305 lung, and 6,744 oesophagus cancer 
patients (Table 1). Pre-pandemic, survival varied significantly by tumour type and referral pathway 
with the worst prognosis evident for oesophageal and lung cancers and with emergency 
presentations. These differences in survival between referral pathways correlated with higher 
proportions of patients diagnosed at stages III and IV, irrespective of tumour type (Table 1, Web-
Appendix page 4). As demonstrated, 2WW referral pathways are not associated with marked 
differences in stage or survival compared to non-urgent referral routes. 
The estimations were undertaken over a 12-month period from 16/03/2020 to 15/03/2021. Across 
Scenarios A-C, we estimate an absolute decline in cancer survival ranging between 1.0% (Breast, all 
scenarios) and 6% (Oesophagus, scenarios B and C) at 1-year, and between 4% (Lung, scenario A) and 
6% (Colorectal, scenario C), 5 years after diagnosis (Table 1).  
The differences in survival translate into substantial additional number of deaths due to cancer in 
the first five years of follow-up. Table 2 presents the estimated number of deaths due to each cancer 
up to 1, 3 and 5 years following diagnosis prior to the pandemic and across scenarios A to C. The 
number of additional deaths estimated across the scenarios are presented as cumulative estimates 
up to year 5 (Table 2 and Figure 2).  
We estimate across scenarios A to C, compared to pre-pandemic, a 2-7% increase in the number of 
deaths due to breast cancer in Year 1 (corresponding to between 20 (15-25) and 63 (57-70) 
additional deaths), a 7-9% increase up to Year 3 (169 (159-179)-228 (218-239) additional deaths) and 
an 8-10% increase up to Year 5 (281 (266-295)-344 (329-358) additional deaths). For colorectal 
cancer, we estimate across scenarios A to C a 18-20% increase in deaths due to cancer in Year 1 (921 
(894-970)-1,027 (999-1,094) additional deaths), a 16-18% increase up to Year 3 (1,301 (1,257-1,411)-
1,414 (1,371-1,568) additional deaths) and a 15-17% increase up to Year 5 (1,445 (1,392-1,591)-
1,563 (1,534-1,592) additional deaths). For lung cancer across scenarios A to C, we estimate a 6-8% 
increase in number of deaths due to cancer in Year 1 (1,102 (1,087-1,117)-1,412 (1,379-1,447) 
additional deaths), a 5-6% increase up to Year 3 (1,231 (1,216-1,249)-1,412 (1,381-1,442) additional 
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deaths), and a 5% increase up to Year 5 (1,235 (1,220-1,254) -1,372 (1,343-1,401) additional deaths). 
For oesophageal cancer, across scenarios A to C, we estimate a 9-10% increase in deaths due to 
cancer in Year 1 (339 (334-343)-377 (372-383) additional deaths), a 6-7% increase up to Year 3 (343 
(337-348)-359 (354-365) additional deaths) and a 6% increase up to Year 5 (330 (324-335)-342 (336-
348) additional deaths).  
The plateau in additional deaths due to cancer over the 5-year period for lung and oesophageal 
cancer reflects relatively higher proportions of early cancer deaths at Year 1 due to more advanced 
stage at presentation in our scenarios. Pre-pandemic, some of these patients would have been 
expected to die beyond Year 1 as a result of less advanced disease at presentation compared to the 
pandemic scenarios.  
Overall, in comparison with the pre-pandemic period, the estimated total number of additional deaths 
attributable to these four cancers at 5 years is between 3,291 and 3,620 deaths across the scenarios 
due to delays in cancer diagnosis (Table 2, Figure 2). These additional cancer deaths in the first few 
years after diagnosis translate into years of life expectancy lost by the entire cohort of patients. At 5 
years, across scenarios A to C, the total additional years of life lost for breast cancer was estimated to 
range from 8,181 (7,797-8,535) to 9,261 (8,843-9,631) years, for colorectal cancer from 25,583 
(24,792-27,744) to 27,735 years (27,188-28,241), for lung cancer from 20,413 (19,833-20,909) to 
20,860 (20,250-21,277) years and for oesophageal cancer from 5,027 (4,861-5,213) to 5,373 (5,227-
5,530) years.  In total we estimate between 59,203 to 63,229 years of life expectancy lost because of 
additional deaths due to these four cancers in the first five years after diagnosis (Table 3).  
Discussion  
We find that across four major tumour types: breast, colorectal, lung and oesophageal cancer, there 
will be an estimated 3,291 to 3,620 avoidable deaths and an additional 59,203 to 63,229 years of life 
lost that are attributable to delays in cancer diagnosis alone. The increase in cancer related deaths up 
to 5 years from diagnosis ranged from 5% for lung cancer to 17% for colorectal cancer. These 
additional deaths are projected to occur as a consequence of the national COVID-19 pandemic 
measures reducing the number of people seeking health care as well as reducing access to and 
availability of diagnostic services. Our findings complement those from a recent study by Sud et al.22 
demonstrating the impact of treatment delay, predominantly surgical, on excess mortality. 
Some essential diagnostic services are currently suspended (e.g. endoscopy) even through the urgent 
2WW referral pathway. This is due to the perceived risk of SARS-COV2 virus exposure for patients and 
clinicians, and because of re-deployment of staff towards critical care to manage COVID-19 cases. This 
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will result in further delays, which could impact on survival, that are not included in our model. Our 
results also highlight the significant proportion of patients diagnosed with cancer through routine 
outpatient referral pathways (30-40%) and the subsequent impact of deferral and delay within these 
referral pathways during the pandemic. Even when routine diagnostic services are re-initiated it is 
anticipated that there will be significant delays in routine and 2WW pathway referrals due to backlogs 
currently building up across all benign and malignant medical and surgical sub-specialities.  
Changes in health seeking behaviour have meant that routine referrals from GPs have reduced in 
volume because patients are being asked to only present if they have significant or urgent concerns.12 
In addition, it is unknown whether the increasing number of remote consultations via telephone or 
videoconferencing will result in a greater proportion of missed diagnoses without the ability to 
examine and triage the patient directly.  
Conversely, increased diagnostic efficiency has potentially been introduced into the system as a 
result of the pandemic. For example, those patients who now report a symptom to their GP are an 
enriched population compared to those reporting pre-COVID and potentially more likely to have 
cancer. Similarly, GP selection for investigation will most likely enrich the population further. 
However, these impacts are likely to be small when considering concerns about the overall shortfall 
in numbers of new cancer diagnoses. In addition, 2WW referrals are still not operating at their usual 
pre-pandemic level, particularly for endoscopic intervention.   
Our findings therefore reflect the urgent need for policy interventions to mitigate the predicted 
additional cancer deaths resulting from delays in diagnosis. Key areas to consider include public health 
messaging; the public’s perception of their personal risk of severe illness from COVID-19 versus the 
risks of not seeking healthcare advice if symptomatic; provision of evidence-based information to 
enable health care workers to adequately risk manage patients during the pandemic with respect to 
the balance of risk and benefit of procedures; and to consider options and opportunities for increasing 
diagnostic capacity.  
In the UK, the ‘Stay at Home’ and subsequent ‘Stay Alert’ public health messaging has had a marked 
impact on health seeking behaviour.23 Even as lockdown measures are being relaxed, presentation to 
primary care services continues to be much lower than pre-pandemic levels, and it cannot be assumed 
that, once all restrictions have been lifted, this will return to the pre-pandemic levels in a reasonable 
timeframe. Any exit strategy from lockdown24 therefore needs to include accurate and measured 
public health messaging that is tailored towards patients, GPs and secondary care services that puts 
into perspective the infection fatality risk of COVID-19 compared to other serious illnesses. Dedicated 
cancer awareness programmes will need to consider a range of media channels to reach their target 
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groups, including direct messaging from GPs to their patients to seek attention if they are experiencing 
new or concerning symptoms.  
Increasing diagnostic capacity is complex as this necessitates effective coordination across all hospital 
sub-specialities and not just within specialist cancer teams. In addition, the requirement for full 
personal protective equipment (PPE) when performing procedures and the initiation of robust 
cleaning protocols between patients has reduced capacity compared to pre-pandemic levels. In the 
short term, diagnostic capacity can be increased through changes in working patterns: longer working 
hours, 7 days-a-week working. In addition, a central coordinating system for diagnostic investigations 
in a similar vein to ’choose and book’ whereby primary care physicians are able to refer to any NHS 
hospital will optimise use of capacity.25 For bowel cancer detection, surgeons are increasingly using 
new tools such as the faecal immunochemical test26 to triage their patients for investigation to avoid 
unnecessary colonoscopy and CT imaging and therefore improving capacity in this diagnostic pathway.  
The paucity of information for health care workers and patients regarding their risk of contracting 
COVID-19 infection from different health care interactions remains a challenge as hospitals plan 
towards restarting routine services. Antibody testing would increase confidence in clinicians 
performing procedures if ’immunity’ does exist for even a short period.27 The health care community 
need accurate data on the true nosocomial risk of COVID-19 depending on the type of diagnostic 
procedure being undertaken e.g. colonoscopy versus Computerised Tomography scan. When rapid 
antigen testing becomes available routinely, patients requiring investigation can receive testing on the 
day of the procedure and risk managed accordingly. Equally the implication of contracting COVID-19 
needs to be considered, specifically what is the true risk of life-threatening illness and death to be able 
to counsel patients effectively.  
A strength of this study is the use of linked national administrative health records of actual patients 
diagnosed and treated in the NHS for the four tumour types. This provides a robust template for 
understanding the impact of current and predicted changes in availability, access and health seeking 
behaviour in response to the COVID-19 pandemic on cancer survival. This method does not require 
any de novo estimation of changes in cancer outcomes but derives this from previous real-world 
observations. 
We chose the ‘routes to diagnosis’ concept as our method of analysing diagnostic delay to overcome 
some of the challenges raised in the literature regarding the relative risk of death from diagnostic 
delay across tumours.2,28,29 Inconsistencies in the evidence are primarily related to flaws in study 
design where the true onset of symptoms remains unclear. In addition, recent work has pointed to a 
’waiting time paradox’ whereby quicker diagnosis is associated with later stage of presentation; this 
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confounds an assessment of the impact of diagnostic delay on outcome.30,31  It is challenging to model 
the extent and duration of diagnostic delay at the population level given that this is predicated on 
health system factors such as the access and, availability of diagnostic capacity, and patient level 
factors (awareness, symptoms, health seeking behaviour). Our model accounts for both and is 
grounded in the reality of current service levels in the English NHS by providing best/worst case 
estimates. We acknowledge that our approach may under- or over-estimate the impact of diagnostic 
delay on survival and retrospective evaluation will be necessary to further appraise this modelling 
approach.  
Our model assumes that disruptions due to the COVID-19 pandemic will impact timely access to 
routine and urgent diagnostic services as well as alter health seeking behaviour for a 12-month period. 
This is likely given the changes in patterns of patient presentation and availability of diagnostic services 
observed since the lockdown. As well as the suspension of screening, the first three months has seen 
a significant reduction in 2WW referrals10 as we predict in Scenario B. Scenario A conservatively 
considers no reduction in 2WW referrals. Given the ongoing reductions in 2WW referral volumes 
(estimates suggest a 40-50% reduction),32 this is expected to continue for up to 6 months as predicted 
in scenario C due to the effects of pandemic lockdown measures on health care presentations. This 
includes, advice to minimise non-essential travel and the continued shielding of at-risk groups.1,12 
Cancer Research UK have estimated that the first 10 weeks of the UK lockdown has already resulted 
in 2.1 million deferred cancer screening investigations with 290,000 fewer people being referred on 
2WW pathways.32 
Following this six-month period there will be a considerable backlog of patients with potential 
cancers awaiting investigation whilst healthcare presentations will continue to be impacted due to 
social distancing measures that are expected until 2021.11,12 Additionally NHS hospital Trusts 
suspended their routine diagnostic services at the start of the lockdown.  This is a concern as routine 
referral routes account for 30-40% of cancer diagnoses and the backlog in this pathway once routine 
services restart will include all patients still awaiting diagnostic investigations both pre-pandemic 
and during the pandemic. Further competition for capacity will subsequently arise from the surge in 
new referrals for suspected cancers on 2WW referrals and those referred for investigation or follow-
up of seemingly benign health conditions. At the same time diagnostic capacity has decreased for 
some procedures due the greater time taken per case since the introduction of new infection control 
measures. Together all these factors will increase the likelihood of patients becoming symptomatic 
and presenting via 2WW referral or emergency pathways. Alternatively, if and when diagnosed 
through routine pathways there is an increased likelihood of stage migration and associated poorer 
prognosis due to delays in diagnosis.  
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Our analysis uses a retrospective population cohort and we therefore note that the predicted 
survival for patients presenting via the different referral pathways, even for patients with stage IV 
disease, has marginally improved33 given the evolution in treatments and processes of care. 
However, our analysis focuses on the differences in cancer deaths between two situations (pre-
pandemic and pandemic) and not on the absolute numbers of cancer deaths. In addition, these 
estimates do not consider the impact of treatment delay or suboptimal treatment on survival during 
the pandemic.22 The proportions of patients presenting through different referral pathways has 
changed over time which may also impact on our results.34 However, we consider the likely impact 
on the overall results to be small given the steady trajectories of improvements we have seen over 
the past five years.  
We did not analyse patients aged 85 years or over at diagnosis as competing events, such as deaths 
from other causes are predominant. Although delays in cancer diagnosis in the elderly will lead to 
excess short-term cancer mortality, the impact on society is likely to be less. Furthermore, given we 
report up-to 5-year survival, such an estimate is less reliable in over 90’s.  
In the screening population we recognise that not all patients diagnosed with breast cancer through 
this route would have progressed or developed symptomatic disease. As a result, we include only 25% 
of this cohort in our re-allocation. For colorectal cancer, 10% of patients are diagnosed through the 
screening route of which 45% are diagnosed with Stage III/IV disease (70% Stage II-IV) compared to 
6% diagnosed with Stage III/IV through breast cancer screening. Over-diagnosis and over-treatment 
are not specific concerns associated with the bowel screening programme35 and the suspension of the 
programme is likely to result in delayed presentation and stage migration if untreated.36  
Our model also considers the English NHS as a whole and therefore assigns blanket reallocation across 
the country. However, there is variation across the country with respect to GP access, the burden of 
COVID-19 and the extent of discontinuation of critical diagnostic services within secondary care 
settings. In this regard we acknowledge that 2WW referrals have not fallen uniformly by 80% across 
all tumour types and UK regions, as per our estimations in Scenarios B and C. In addition, there will be 
variation in the recovery of services across regions and individual hospitals, which are not included in 
our estimations.  
In conclusion we demonstrate that changes in health seeking behaviour and the availability of and 
access to essential diagnostic services resulting from national pandemic measures will result in 
significant additional deaths from breast, colorectal, lung and oesophageal cancer in the medium (1 
year) and longer term (5 years). The study results do not consider the effect of delay on other cancer 
types, or the additional impact of changes in treatment pathways for these cancers which are likely to 
Accepted Manuscript 19.06.20. The Lancet Oncology (in press) 
 
16 
 
significantly increase the expected avoidable deaths beyond what we have estimated. Urgent policy 
interventions are necessary to mitigate the indirect effects of the national COVID-19 pandemic on 
cancer patients. These should focus on increasing routine diagnostic capacity through which up to 40% 
of cancer patients are diagnosed, public health messaging that accurately conveys the risk of severe 
illness from COVID-19 versus the risks of not seeking healthcare advice if symptomatic, and the 
provision of evidence-based information for clinicians to adequately risk-manage patients as to the 
risk and benefits of procedures during the pandemic. 
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Research in context  
Evidence before this study 
In the UK, national COVID-19 pandemic measures since 16rd March 2020 have resulted in the 
suspension of cancer screening and deferral of routine diagnostic investigations. In addition, urgent 
two-week wait suspected cancer referrals initiated by General Practitioners (GPs) have fallen by up 
to 80% in response to social distancing. To identify studies reporting on the current or predicted 
impact of diagnostic delay on cancer mortality during the COVID-19 pandemic we conducted a 
literature search of PubMed from 01/01/2020 to 30/04/2020 in order to identify national estimates 
and methods of estimation. Search terms included (COVID-19 OR coronavirus OR SARS-Cov-2) AND 
cancer AND (diagnosis OR diagnostic) AND delay. To date, no study has attempted to model the 
impact of changes in health seeking behaviour and in the availability and access to diagnostic 
services as a result of the COVID-19 lockdown on cancer survival and the additional number of 
deaths expected.  
Added value of this study  
Our study presents the results of an innovative method that uses a ‘routes to diagnosis’ validated 
framework to estimate the impact of the delays in diagnosis that we are seeing on cancer survival 
and excess cancer deaths for four tumour types: breast, colorectal, lung and oesophageal cancer. 
Using linked national cancer registration and hospital administrative datasets, we have modelled the 
impact across three pragmatic scenarios that reflect actual changes in the diagnostic pathway being 
observed in the National Health Service (NHS).  
Implications of all the available evidence  
We find that across four major tumour types there will be an estimated 3,291 to 3,620 avoidable 
excess deaths up to 5 years from diagnosis. This equates to approximately 60,000 years of lost life 
for just these four tumour types that we attribute to delays in diagnosis. Our results are conservative 
estimates as we do not consider the impact of suboptimal or delayed cancer treatment. This data is 
essential for policymakers to drive changes in national lockdown and stay-at-home messaging, as 
well as to urgently reduce diagnostic delay, particularly for routine investigations, through outreach 
and accessibility programmes. This model can also be utilised by other countries in their unique 
healthcare settings to understand the impact of delays in diagnosis on cancer outcomes. 
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Figure Legends 
 
Figure 1. Conceptual framework for the modelling scenarios. 
Notes:  
1. 2WW – Two week wait urgent suspected cancer referrals; EP – Emergency presentation 
2. For Breast cancer note that in addition to patients on routine pathways only 25% (n= 2700) 
of patients diagnosed through screening (i.e. the proportion of patients with T3, T4, Node 
positive, or Metastatic disease) are reallocated to 2WW/EP in the pandemic scenarios (see 
Methods section). 
 
Figure 2. Estimated additional numbers of deaths due to cancer for each pandemic scenario A-C, 
by tumour type.  
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Figure 1. Conceptual framework for the modelling scenarios 
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          1 2 3   4 5 6   7 8 9 10 11 12   
                                        
  
 
  
 
  
    
2WW / EP 
  
Pre-pandemic  
Referral routes                                     
2WW         2WW (20% capacity) 
EP 
  
2WW / EP 
  
EP             
GP Routine                                    
Routine (outpatients)                    
Routine (inpatients)       2WW (20% capacity) 
EP 
  2WW (75% capacity) 
EP 
  
2WW / EP 
  
Screening               
                                        
                                        
 
Notes:  
1. 2WW – Two week wait urgent suspected cancer referrals; EP – Emergency presentation 
2. For Breast cancer note that in addition to patients on routine pathways only 25% (n= 2700) of patients diagnosed through screening (i.e. the 
proportion of patients with T3, T4, Node positive, or Metastatic disease) are reallocated to 2WW/EP in the pandemic scenarios (see Methods 
section). 
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Table 1. Distribution of patients by referral pathway, and 1-, 3- and 5-year net survival (NS), pre-
pandemic and by each pandemic scenario (A-C) 
  Distribution of patients Stages III-IV 
(%) 
  1-year   3-year   5-year 
  N %   NS (95% CI)   NS (95% CI)   NS (95% CI) 
Breast cancer                  
Pre-pandemic                  
EP 930 2.9 68.8  56.3 (53.9-58.6)   39.0 (37.0-41.0)   33.4 (31.8-35.1) 
GP referral 5,136 15.8 20.0  96.3 (96.2-96.3)   90.0 (89.9-90.1)   86.2 (86.2-86.3) 
Other routine 887 2.7 22.2  94.0 (93.8-94.2)   85.8 (85.5-86.1)   81.3 (81.0-81.7) 
Screening 10,795 33.1 6.0  100 (100-100)   99.6 (99.6-99.6)   98.8 (98.8-98.8) 
2WW 14,835 45.5 20.4  97.9 (97.9-97.9)   91.3 (91.3-91.4)   86.3 (86.2-86.3) 
                   
Overall 32,583 100    97.0 (97.0-97.1)   92.2 (92.2-92.3)   88.8 (88.7-88.8) 
                    
Scenario A                   
EP 1,149 4.7    
96.0 (95.9-96.1) 
  
89.0 (88.9-89.1) 
  
83.9 (83.9-84) 
2WW 23,357 95.3        
                    
Scenario B                   
EP 1,225 5.0    
95.9 (95.9-96) 
  
88.8 (88.7-88.9) 
  
83.6 (83.6-83.7) 
2WW 23,286 95.0        
                    
Scenario C                   
EP 1,249 5.1    
95.9 (95.8-96) 
  
88.7 (88.6-88.8) 
  
83.6 (83.5-83.6) 
2WW 23,240 94.9        
                   
Colorectal cancer              
Pre-pandemic Colon / Rectum Colon / Rectum Colon / Rectum             
EP 4,143 / 1,040 26.1 / 11.4 77.5 / 78.6   54.8 (54.6-55.1)   40.3 (40.1-40.4)   35.1 (34.9-35.2) 
GP referral 3,769 / 2,538 23.8 / 27.9 60.6 / 59.0   83.5 (83.4-83.5)   70.6 (70.5-70.7)   64.4 (64.3-64.4) 
Other routine 2,063 / 1,001 13.0 / 11.0 59.9 / 62.2   83.7 (83.6-83.8)   71.3 (71.2-71.4)   65.4 (65.3-65.5) 
Screening 1,922 / 1,102 12.1 / 12.1 43.8 / 45.3   97.5 (97.5-97.5)   92.9 (92.9-93.0)   89.6 (89.6-89.7) 
2WW 3,970 / 3,427 25.0 / 37.6 61.1 / 61.8   85.0 (85.0-85.1)   71.2 (71.2-71.3)   64.2 (64.1-64.2) 
                   
Overall 15,867/9,108 100 / 100     79.7 (79.7-79.8)   67.3 (67.2-67.3)   61.4 (61.4-61.5) 
                   
Scenario A                  
EP 6,166 / 1,570 38.9 / 17.2    
76.0 (75.9-76.0) 
  
61.9 (61.8-61.9) 
  
55.3 (55.3-55.3) 
2WW 9,700 / 7,538 61.1 / 82.8        
                  
Scenario B                 
EP 6,384 / 1,654 40.2 / 18.2    
75.7 (75.6-75.7) 
  
61.6 (61.6-61.7) 
  
55.1 (55.1-55.2) 
2WW 9,482 / 7,454 59.8 / 81.8        
                   
Scenario C                  
EP 6,456 / 1,678 40.7 / 18.4    
75.5 (75.5-75.6) 
  
61.5 (61.4-61.5) 
  
55.0 (55.0-55.0) 
2WW 9,410 / 7,430 59.3 / 81.6        
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Lung cancer                  
Pre-pandemic                   
EP 9,636 32.9 88.3   15.9 (15.9-15.9)   6.6 (6.6-6.6)   4.6 (4.6-4.6) 
GP referral 6,549 22.3 68.1   46.4 (46.4-46.4)   26.1 (26.1-26.1)   19.6 (19.6-19.6) 
Other routine 4,003 13.7 66.5   50.3 (50.3-50.4)   29.1 (29.1-29.1)   22.0 (22.0-22.0) 
2WW 9,117 31.1 76.3   48.7 (48.7-48.7)   21.9 (21.9-21.9)   13.6 (13.6-13.6) 
                   
Overall 29,305 100    37.6 (37.6-37.6)   18.8 (18.8-18.8)   13.1 (13.1-13.1) 
                   
Scenario A                  
EP 12,802 43.7    
34.1 (34.0-34.1) 
  
15.1 (15.1-15.1) 
  
9.6 (9.6-9.6) 
2WW 16,503 56.3        
                  
Scenario B                 
EP 13,715 46.8    
33.3 (33.3-33.3) 
  
14.7 (14.7-14.7) 
  
9.4 (9.4-9.4) 
2WW 15,590 53.2        
                  
Scenario C                 
EP 13,538 46.2    
33.1 (33.1-33.1) 
  
14.6 (14.6-14.6) 
  
9.3 (9.3-9.3) 
2WW 15,767 53.8        
                   
Oesophageal cancer                 
Pre-pandemic                   
EP 1,228 18.2 91.2   20.7 (20.3-21.1)   9.5 (9.4-9.7)   7.9 (7.8-8.1) 
GP referral 1,410 20.9 71.7   54.8 (54.6-55.0)   27.3 (27.2-27.4)   21.2 (21.0-21.3) 
Other 1,303 19.3 73.1   55.7 (55.6-55.9)   29.7 (29.6-29.9)   23.9 (23.7-24.0) 
2WW 2,803 41.6 83.3   48.2 (48.1-48.3)   19.1 (19.0-19.2)   13.4 (13.3-13.5) 
                    
Overall 6,744 100     46.0 (45.9-46.1)   21.1 (21.1-21.2)   16.1 (16.0-16.1) 
                    
Scenario A                  
EP 1,690 25.1    
41.3 (41.2-41.4) 
  
16.7 (16.7-16.8) 
  
12.0 (12.0-12.1) 
2WW 5,054 74.9        
                   
Scenario B                  
EP 1,783 26.4    
39.9 (39.7-40.0) 
  
15.8 (15.7-15.8) 
  
11.3 (11.3-11.4) 
2WW 4,961 73.6        
                   
Scenario C                  
EP 1,812 26.9    
39.7 (39.6-39.8) 
  
15.7 (15.7-15.8) 
  
11.3 (11.2-11.3) 
2WW 4,932 73.1        
 
 
Notes:  
1. NS - Net survival; EP - Emergency Presentation; 2WW - Two-week wait urgent suspected 
cancer referral.  
2. ‘Other routine’ includes referrals within secondary care. 
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3. Net survival for colorectal cancer is for both colon and rectum tumour type combined. 
However, allocation of patients to 2WW and EP diagnostic routes was done separately for 
each tumour type. 
4. For Breast cancer note that in addition to patients on routine pathways only 25% (n= 2700) 
of patients diagnosed through screening (i.e. the proportion of patients with T3, T4, Node 
positive, or Metastatic disease) are reallocated to 2WW/EP in the pandemic scenarios (see 
Methods section)
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Table 2. Estimated cumulative number of deaths due to cancer up to Years 1, 3 and 5, pre-pandemic and for each pandemic scenario A-C (also presented as 
additional number of deaths) 
            Additional number of deaths due to cancer 
   Number of deaths due to cancer   up-to 1 year   up-to 3 years   up-to 5 years 
    
up-to 1 year  
(95% CI) 
up-to 3 years  
(95% CI) 
up-to 5 years  
(95% CI)   N (95% CI) %*   N (95% CI) %*   N (95% CI) %* 
Breast (N = 32,583)                       
Pre-pandemic   965 (958-972) 2,495 (2,484-2,505) 3,565 (3,554-3,577)                   
Scenario A   985 (977-993) 2,664 (2,651-2,676) 3,846 (3,831-3,861)   20 (15-25) 2.1   169 (159-179) 6.8   281 (266-295) 7.9 
Scenario B   1,018 (1,009-1,026) 2,709 (2,696-2,722) 3,894 (3,876-3,911)   53 (47-59) 5.5   214 (202-226) 8.6   329 (313-344) 9.2 
Scenario C   1,028 (1,019-1,036) 2,723 (2,709-2,737) 3,908 (3,890-3,926)   63 (57-70) 6.6   228 (218-239) 9.1   344 (329-358) 9.6 
Colorectum (N = 24,975)                       
Pre-pandemic   5,051 (5,004-5,099) 8,056 (8,007-8,109) 9,417 (9,367-9,470)                   
Scenario A   5,986 (5,943-6,025) 9,436 (9,391-9,475) 10,980 (10,940-11,020)   935 (918-953) 18.5   1,379 (1,354-1,405) 17.1   1,563 (1,534-1,592) 16.6 
Scenario B   5,972 (5,929-6,028) 9,357 (9,299-9,459) 10,862 (10,797-10,995)   921 (894-970) 18.2   1,301 (1,257-1,411) 16.1   1,445 (1,392-1,591) 15.3 
Scenario C   6,078 (6,032-6,140) 9,470 (9,409-9,613) 10,972 (10,903-11,162)   1,027 (999-1,094) 20.3   1,414 (1,371-1,568) 17.6   1,555 (1,498-1,760) 16.5 
Lung (N = 29,305)                           
Pre-pandemic   18,443 (18,388-18,503) 24,138 (24,097-24,172) 25,934 (25,901-25,963)                   
Scenario A   19,545 (19,497-19,594) 25,369 (25,339-25,398) 27,170 (27,148-27,191)   1,102 (1,087-1,117) 6.0   1,231 (1,216-1,249) 5.1   1,235 (1,220-1,254) 4.8 
Scenario B   19,769 (19,721-19,817) 25,498 (25,464-25,531) 27,267 (27,240-27,297)   1,326 (1,295-1,362) 7.2   1,360 (1,331-1,389) 5.6   1,332 (1,306-1,360) 5.1 
Scenario C   19,855 (19,804-19,901) 25,549 (25,519-25,582) 27,306 (27,280-27,334)   1,412 (1,379-1,447) 7.7   1,412 (1,381-1,442) 5.8   1,372 (1,343-1,401) 5.3 
Oesophagus (N = 6,744)                     
Pre-pandemic   3,656 (3,642-3,670) 5,359 (5,349-5,369) 5,730 (5,720-5,741)                   
Scenario A   3,995 (3,978-4,012) 5,701 (5,690-5,714) 6,060 (6,049-6,073)   339 (334-343) 9.3   343 (337-348) 6.4   330 (324-335) 5.8 
Scenario B   4,024 (4,006-4,041) 5,714 (5,703-5,726) 6,069 (6,058-6,081)   367 (362-373) 10.1   355 (350-361) 6.6   339 (333-345) 5.9 
Scenario C   4,034 (4,017-4,050) 5,718 (5,707-5,731) 6,072 (6,061-6,084)   377 (372-383) 10.3   359 (354-365) 6.7   342 (336-348) 6.0 
 
Notes:  
1. Point estimates and 95% confidence intervals were calculated from bootstrap samples of the original data. 
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2. For Breast cancer note that in addition to patients on routine pathways only 25% (n= 2700) of patients diagnosed through screening (i.e. the 
proportion of patients with T3, T4, Node positive, or Metastatic disease) are reallocated to two-week wait urgent cancer referral (2WW) or 
Emergency Presentation (EP) in the pandemic scenarios (see Methods section).
Accepted Manuscript 19.06.20. The Lancet Oncology (in press) 
 
28 
 
Table 3. Estimated Years of life lost (YLL) resulting from additional deaths due to cancer up to 5 years 
from diagnosis for each pandemic scenarios A-C. 
 
    N (95% CI) 
Breast (N = 32,583)   
Scenario A   8,181 (7,797-8,535) 
Scenario B   9,033 (8,638-9,390) 
Scenario C   9,261 (8,843-9,631) 
Colorectum (N = 24,975)     
Scenario A   27,735 (27,188-28,241) 
Scenario B   25,583 (24,792-27,744) 
Scenario C   27,043 (26,234-29,968) 
Lung (N = 29,305)   
Scenario A   20,537 (20,184-20,947) 
Scenario B   20,860 (20,250-21,277) 
Scenario C   20,413 (19,833-20,909) 
Oesophagus (N = 6,744)     
Scenario A   5,373 (5,227-5,530) 
Scenario B   5,152 (5,006-5,301) 
Scenario C   5,027 (4,861-5,213) 
 
Notes: 
1. For Breast cancer note that in addition to patients on routine pathways only 25% (n= 2700) 
of patients diagnosed through screening (i.e. the proportion of patients with T3, T4, Node 
positive, or Metastatic disease) are reallocated to two-week wait (2WW) urgent referrals or 
emergency presentation (EP) pathways in the pandemic scenarios (see Methods section).  
2. Point estimates and 95% confidence intervals were calculated from bootstrap samples of the 
original data. 
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Figure 2. Estimated additional numbers of deaths due to cancer for each pandemic scenario A-C, by 
tumour type.  
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Technical appendix 
 
The impact of the COVID-19 pandemic on cancer deaths due to delays in 
diagnosis: a national population-based modelling study 
Dr. Camille Maringe PhD, Prof. James Spicer PhD, Dr Melanie Morris PhD, Prof. Arnie Purushotham 
MD, Prof. Ellen Nolte PhD, Prof. Richard Sullivan PhD, Prof. Bernard Rachet PhD, Dr Ajay Aggarwal 
PhD.  
 
1. Re-allocation of patients to new referral pathway 
Main analyses: Each patient had equal probabilities to be reallocated to each of the emergency 
referral routes. We randomly generated their probabilities and selected those patients with random 
values below the thresholds detailed in the paper, and necessary to maintain proportions of patients 
re-allocated to the emergency referral pathway in keeping with the original distributions seen in pre-
pandemic cohorts (see proportions in Table 1). 
 
2. Quantifying net survival and deaths due to cancer 
Baseline, pre-pandemic, levels of cancer-specific survival were assessed through multivariable excess 
hazard models. We use the strcs package in Stata1. strcs implements a two-step method that 
incorporates both analytical and numerical integration to estimate the cumulative hazard function 
required for the log-likelihood function. Flexible parametric survival models are fit using maximum 
likelihood estimation. 
The main assumption of excess hazard models is that the overall mortality of the cohort of patients 
(𝜆) is the sum of two forces of mortality: the excess mortality hazard (𝜆𝐸), assumed to be the 
mortality hazard directly or indirectly due to cancer, and the expected or other causes mortality 
hazard, which is considered to be well approximated by the general population mortality hazard 
(𝜆𝑃).  
𝜆(𝑡, 𝒙) = 𝜆𝐸 (𝑡, 𝒙) + 𝜆𝑃  (𝑎 + 𝑡, 𝑦 + 𝑡, 𝒛), 
The cancer mortality hazard, 𝜆𝐸, at time 𝑡 for given patient’s covariates 𝒙, such as age at diagnosis 
(𝑎), deprivation levels, and referral pathway, is what we need to estimate. The following model is 
fitted: 
𝜆𝐸 (𝑡, 𝒙) = 𝜆0 (𝑡) ∗ 𝑒𝑥𝑝 (𝛽 ∗ 𝒙) 
𝜆𝐸 (i.e. hazard of death due to cancer) was modelled as a function of age at diagnosis (𝑎), 
deprivation (𝑑), and mode of presentation (𝑝) as follows: non-linear effects of age at diagnosis 
(restricted cubic splines, 𝑎1 and 𝑎2) and time-dependent effects of each variable were allowed, as 
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well as interactions between age at diagnosis and deprivation and between age at diagnosis and 
mode of presentation. The excess hazard at the reference value of all covariables, the baseline 
hazard, 𝜆0 (𝑡), was modelled using polynomials of follow-up time defined in three contiguous time 
intervals (restricted cubic splines with 3 degrees of freedom) and smoothly joined at the intervals’ 
boundaries.  
𝜆𝐸  (𝑡, 𝒙) = 𝜆0 (𝑡) ∗ 𝑒𝑥𝑝 (𝛽𝑎,1(𝑡) ∗ 𝑎1 + 𝛽𝑎,2(𝑡) ∗ 𝑎2
+ ∑(𝛽𝑑,𝑗(𝑡) ∗ 𝐼𝑑=𝑗 + 𝛾𝑎,1,𝑗(𝑡) ∗ 𝑎1𝐼𝑑=𝑗 + 𝛾𝑎,2,𝑗(𝑡) ∗ 𝑎2𝐼𝑑=𝑗)
5
𝑗=2
+ ∑(𝛽𝑝,𝑘(𝑡) ∗ 𝐼𝑝=𝑘 + 𝛼𝑎,1,𝑘(𝑡) ∗ 𝑎1𝐼𝑝=𝑘 + 𝛼𝑎,2,𝑘(𝑡) ∗ 𝑎2𝐼𝑝=𝑘)
𝑃
𝑘=2
) 
𝛽𝑎,1 and 𝛽𝑎,2 are the effects of each component of age, 𝛽𝑑,𝑗  are the effects of each deprivation 
quintile 𝑗, 𝑗 = 2, … 5, 𝛽𝑝,𝑘 are the effects of each mode of presentation, and 𝛾𝑎,1,𝑗, 𝛾𝑎,2,𝑗, 𝛼𝑎,1,𝑘, and 
𝛼𝑎,2,𝑘 are the interactive effects on the excess hazard of death. Each effect is allowed to vary with 
follow-up time 𝑡. The best-fitting forms of effects were selected using a hierarchical model selection 
algorithm designed by Royston and Sauerbrei (mfpigen),2,3 combined with the Akaike Criteria (AIC).4 
The effects selected are presented in the Table below. 
When analysing population-based data, the measure of interest, excess mortality due to cancer, is 
conventionally retrieved by removing the impact of competing risks of death, i.e. the deaths from 
causes other than the cancer of interest. These competing risks, derived from general population life 
tables defined by sex, single years of age, calendar years, deprivation quintile, and Government 
Office Regions (𝒛), were assigned to each patient at their date of last known vital status. 
 
Effects selected for each excess hazard model 
The final model selected for each cancer was fitted on the pre-pandemic cohorts of patients. The 
estimated coefficients associated with the effects of each variable and the parameters 
corresponding to the baseline excess hazard were retained. These inform the prediction of excess 
hazard of death due to cancer for each patient 𝑖 at selected times 𝑡, 𝜆𝐸,𝑖(𝑡). Such predictions were 
made for each patient in the setting of the observed pre-pandemic cohorts in addition to the three 
scenarios A-C. From the individual excess hazards, we derived the following quantities: 
Cohort net survival: the survival of the cohort of cancer patients, assuming patients can only die of 
their cancer. 𝑆𝑁,𝑖 is the individual net survival, and 𝑆𝑁 is the cohort net survival, such that: 
𝑆𝑁,𝑖(𝑡, 𝑥𝑖) = exp (− ∫ 𝜆𝐸,𝑖(𝑢, 𝑥𝑖)𝑑𝑢
𝑡
0
) 
Age at diagnosis Referral pathway Deprivation Sex Age* referral Age * deprivation
Breast Non linear, non proportional Categorical, non proportional Categorical Included Included
Colorectum Non linear, non proportional Categorical, non proportional Categorical Proportional Included
Lung Linear, non proportional Categorical, non proportional Categorical Proportional Included Included, non proportional
Oesophagus Non linear, non proportional Categorical, non proportional Categorical Non proportional Included
Main effects Interactions
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𝑆𝑁(𝑡) =
1
𝑁
∑ 𝑆𝑁,𝑖(𝑡, 𝑥𝑖)
𝑁
𝑖=1
 
 
Crude probability of cancer death: this is the probability of cancer-related death for each patient, 
𝐶𝑃𝐷𝐶,𝑖, or on average in the cohort, in the presence of competing risks of deaths. 
𝐶𝑃𝐷𝐶,𝑖(𝑡, 𝑥𝑖) = ∫ 𝑆𝑂,𝑖(𝑢
−|𝑥𝑖) ∗ 𝜆𝐸,𝑖(𝑢, 𝑥𝑖)𝑑𝑢
𝑡
0
 
𝑆𝑂,𝑖(𝑢
−) represent individual overall survival of patient 𝑖, estimated just before time 𝑢. These were 
derived from multivariable hazard models, adjusting for the effects of age at diagnosis, deprivation, 
sex and referral pathway on the overall (all-cause) hazard of death. We performed model selection 
identical to that explained for the excess hazard models. 
Number of deaths due to cancer at time 𝑡, 𝐷𝐶 : these are directly derived from the individual crude 
probabilities of death estimated at time 𝑡. 
𝐷𝐶 (𝑡, 𝑥𝑖) = ∑ 𝐶𝑃𝐷𝐶,𝑖(𝑡|𝑥𝑖)
𝑁
𝑖=1
 
Number of years of life expectancy lost due to cancer: this is the total number of years of life 
expectancy lost due to cancer-related mortality for the cohort of cancer patients. 𝐿𝐸𝐿𝐶 (𝑎, 𝑏, 𝑥𝑖) 
defines the number of years of life expectancy lost due to deaths due to cancer between years 𝑎  
and 𝑏. 
𝐿𝐸𝐿𝐶(0, 𝑡, 𝑥𝑖) = ∑(𝐶𝑃𝐷𝐶,𝑖(0, 𝑡|𝑥𝑖) − 𝐶𝑃𝐷𝐶,𝑖(𝑡, ∞|𝑥𝑖))
𝑁
𝑖=1
∗ ∫ 𝑆𝑖
∗(𝑢|𝑧𝑖)𝑑𝑢
∞
𝑡
 
𝑒𝑥,𝑖(𝑡) = ∫ 𝑆𝑖
∗(𝑢|𝑧𝑖)𝑑𝑢
∞
𝑡
 is the life expectancy of patient 𝑖 at time 𝑡. 
Each of these quantities were compared between the pre-pandemic setting and the 3 scenarios 
explored up to 5 years following diagnosis. The differences provided an estimated decrease in net 
survival, additional number of deaths due to cancer and additional numbers of years of life 
expectancy lost due to cancer, namely: 
𝐷𝑖𝑓𝑓𝐷𝐶
𝑋(𝑡, 𝑥𝑖) = 𝐷𝐶
𝑋
(𝑡, 𝑥𝑖) − 𝐷𝐶
𝑃𝑃(𝑡, 𝑥𝑖) 
Whereby 𝐷𝐶
𝑋is the number of deaths due to cancer in Scenario X (X=A, B, or C) and 𝐷𝐶
𝑃𝑃 is the 
number of deaths due to cancer in the pre-pandemic period, and 
𝐷𝑖𝑓𝑓𝐿𝐸𝐿𝐶
𝑋(0, 𝑡, 𝑥𝑖) = 𝐿𝐸𝐿𝐶
𝑋(0, 𝑡, 𝑥𝑖) − 𝐿𝐸𝐿𝐶
𝑃𝑃(0, 𝑡, 𝑥𝑖) 
We make the conservative assumption that 𝐶𝑃𝐷𝐶,𝑖(𝑡, ∞|𝑥𝑖) are equivalent in the pre-pandemic 
cohort and the cohort in each scenario, leading to: 
𝐷𝑖𝑓𝑓𝐿𝐸𝐿𝐶
𝑋(0, 𝑡, 𝑥𝑖) = ∑(𝐶𝑃𝐷𝐶,𝑖
𝑋(0, 𝑡|𝑥𝑖) − 𝐶𝑃𝐷𝐶,𝑖
𝑃𝑃(0, 𝑡|𝑥𝑖))
𝑁
𝑖=1
∗ ∫ 𝑆𝑖
∗(𝑢|𝑧𝑖)𝑑𝑢
∞
𝑡
 
For the later, only the figures at 5 years were calculated and presented.  
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We provide the point estimates and their 95% CI around the estimations of 𝐶𝑃𝐷𝐶 , 𝐷𝐶 , and 𝐿𝐸𝐿𝐶  
based on bootstrap samples.5,6  
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Appendix Figure 1 
1-, 3- and 5-year net survival, by referral pathway and overall pre-pandemic and by scenarios A-C 
 
